On October 18, 2024, the Phase I clinical trial of the fungal DHODH inhibitor SG1001 developed by sungening Biotechnology in China was officially launched under the promotion of its partner Lizhu Pharmaceutical, and the first subject was administered.
The Phase I clinical trial of SG1001 aims to evaluate its safety and pharmacokinetic characteristics, and the project is progressing rapidly and steadily according to the expected research plan. The successful completion of the first subject administration in the Phase I clinical trial is an important milestone for the company's R&D pipeline, indicating that the development process of the company's pipeline has entered the top tier globally. We hope that with the trust and support of patients, their families, researchers, and clinical research centers, SG1001, this innovative therapy, can soon benefit Chinese fungal infection patients.
sungening Biotech sincerely thanks the relevant cooperative units of SG1001 project, including Lizhu Pharmaceutical, Kailaiying, Xinlitai, Medixi, Jianjin Pharmaceutical, Chengdu Haibowei, Pulemei, Peking University First Hospital, etc.
About SG1001
Dihydroorotate dehydrogenase (DHODH) is an oxidoreductase that catalyzes the de novo biosynthesis of pyrimidine, converting dihydroorotate to orotate. It is a key enzyme in fungal pyrimidine biosynthesis. SG1001 tablets selectively inhibit fungal DHODH, thereby suppressing fungal pyrimidine biosynthesis, affecting cell wall formation, and inhibiting fungal growth. At present, the product has obtained domestic clinical trial approval and is intended for the treatment of invasive fungal diseases.
